Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

P53 Arg72Pro Polymorphism and Bladder Cancer Risk - Meta-analysis Evidence for a Link in Asians but not Caucasians

  • Xu, Ting (Department of Urologic Surgery, The Affiliated Cancer Hospital of Jiangsu Province, Nanjing Medical University) ;
  • Xu, Zi-Cheng (Department of Urologic Surgery, The Affiliated Cancer Hospital of Jiangsu Province, Nanjing Medical University) ;
  • Zou, Qin (Department of Urologic Surgery, The Affiliated Cancer Hospital of Jiangsu Province, Nanjing Medical University) ;
  • Yu, Bin (Department of Urologic Surgery, The Affiliated Cancer Hospital of Jiangsu Province, Nanjing Medical University) ;
  • Huang, Xin-En (Department of Chemotherapy, the Affiliated Cancer Hospital of Jiangsu Province, Nanjing Medical University)
  • Published : 2012.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: Individual studies of the associations between P53 codon 72 polymorphism (rs1042522) and bladder cancer susceptibility have shown inconclusive results. To derive a more precise estimation of the relationship, we performed this systemic review and meta-analysis based on 15 publications. Methods: We used odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of the association. Results: We found that there was no association between P53 codon 72 polymorphism and bladder cancer risk in the comparisons of Pro/Pro vs Arg/Arg; Pro/Arg vs. Arg/Arg; Pro/Pro plus Pro/Arg vs. Arg/Arg; Arg/Arg vs. Pro/Arg plus Arg/Arg (OR=1.06 95%CI 0.81-1.39; OR=1.06 95%CI 0.83-1.36; OR=0.98 95%CI 0.78-1.23; OR=1.06 95%CI 0.84-1.32). However, a significantly increased risk of bladder cancer was found among Asians in the homozygote comparison (Pro/Pro vs. Arg/Arg, OR=1.36 95%CI 1.05-1.75, P=0.790 for heterogeneity) and the dominant model (Arg/Pro plus Pro/Pro vs. Arg/Arg, OR=1.26 95%CI 1.05-1.52, P=0.564 for heterogeneity). In contrast, no evidence of an association between bladder cancer risk and P53 genotype was observed among Caucasian population in any genetic model. When stratifying for the stage of bladder, no statistical association were found (Pro/Pro vs. Arg/Arg, OR=0.45 95%CI 0.17-1.21; Pro/Arg vs. Arg/Arg, OR=0.60 95%CI 0.28-1.27; Dominant model, OR=0.56 95%CI 0.26-1.20; Recessive model, OR=0.62 95%CI0.35-1.08) between P53 codon 72 polymorphism and bladder cancer in all comparisons. Conclusions: Despite the limitations, the results of the present meta-analysis suggest that, in the P53 codon 72, Pro/Pro type and dominant mode might increase the susceptibility to bladder cancer in Asians; and there are no association between genotype distribution and the stage of bladder cancer.

Keywords

References

  1. Biro E, Kalina I, Salagovic J, et al (2000). p53 single nucleotide polymorphisms and bladder cancer. Neoplasma, 47, 303-6.
  2. Bryan RT, Hussain SA, James ND, et al (2005). Molecular pathways in bladder cancer: part 2. BJU Int, 95, 491-6. https://doi.org/10.1111/j.1464-410X.2005.05326.x
  3. Chang CC, Hsieh YY, Tsai FJ, et al (2002). The proline form of p53 codon 72 polymorphism is associated with endometriosis. Fertil Steril, 77, 43-5. https://doi.org/10.1016/S0015-0282(01)02938-7
  4. Chen WC, Tsai FJ, Wu JY, et al (2000). Distributions of p53 codon 72 polymorphism in bladder cancer--proline form is prominent in invasive tumor. Urol Res, 28, 293-6. https://doi.org/10.1007/s002400000117
  5. Chung CJ, Huang CJ, Pu YS, et al (2008). Polymorphisms in cell cycle regulatory genes, urinary arsenic profile and urothelial carcinoma. Toxicol Appl Pharmacol, 232, 203-9. https://doi.org/10.1016/j.taap.2008.06.011
  6. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  7. Dumont P, Leu JI, Della Pietra AC, 3rd, et al (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet, 33, 357-65. https://doi.org/10.1038/ng1093
  8. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  9. Gao LL, Huang XE, Zhang Q, et al (2011). 14.A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
  10. Gong P, Huang XE, Chen CY, et al (2012). Comparison on complications of peripherally inserted central catheters by ultrasound guide or conventional method in cancer patients. Asian Pacific J Cancer Prev, (in press).
  11. Herr HW, Sogani PC (2001). Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol, 166, 1296-9. https://doi.org/10.1016/S0022-5347(05)65756-4
  12. Horikawa Y, Nadaoka J, Saito M, et al (2008). Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncol Rep, 20, 49-55.
  13. Huang XE, Li CG, Li Y, et al (2011). Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a Phase II trial. Asian Pacific J Cancer Prev, 12, 2797-800.
  14. Jemal A, Siegel R, Xu J, et al (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300. https://doi.org/10.3322/caac.20073
  15. Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy. Asian Pacific J Cancer Prev, 11, 1059-62.
  16. Kaufman DS, Shipley WU, Feldman AS (2009). Bladder cancer. Lancet, 374, 239-49. https://doi.org/10.1016/S0140-6736(09)60491-8
  17. Klug SJ, Ressing M, Koenig J, et al (2009). TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol, 10, 772-84. https://doi.org/10.1016/S1470-2045(09)70187-1
  18. Kuroda Y, Tsukino H, Nakao H, et al (2003). p53 Codon 72 polymorphism and urothelial cancer risk. Cancer Lett, 189, 77-83. https://doi.org/10.1016/S0304-3835(02)00518-9
  19. Levine AJ (1997). p53, the cellular gatekeeper for growth and division. Cell, 88, 323-31. https://doi.org/10.1016/S0092-8674(00)81871-1
  20. Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of $OxyContin^{(R)}$ administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8.
  21. Li CG, Huang XE, Li Y, et al (2011). Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pacific J Cancer Prev, 12, 487-90.
  22. Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients. Asian Pacific J Cancer Prev, 13, 301-4. https://doi.org/10.7314/APJCP.2012.13.1.301
  23. Lin HY, Yang MC, Huang CH, et al (2011) Polymorphisms of TP53 are markers of bladder cancer vulnerability and prognosis. Urol Oncol. 2011 Dec 16.
  24. Li Y, Yan PW, Huang XE, et al (2011). MDR1 Gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pacific J Cancer Prev, 12, 2405-9.
  25. Mabrouk I, Baccouche S, El-Abed R, et al (2003). No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann N Y Acad Sci, 1010, 764-70. https://doi.org/10.1196/annals.1299.137
  26. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  27. Meek DW (2004). The p53 response to DNA damage. DNA Repair (Amst), 3, 1049-56. https://doi.org/10.1016/j.dnarep.2004.03.027
  28. Pandith AA, Shah ZA, Khan NP, et al (2010). Role of TP53 Arg72Pro polymorphism in urinary bladder cancer predisposition and predictive impact of proline related genotype in advanced tumors in an ethnic Kashmiri population. Cancer Genet Cytogenet, 203, 263-8. https://doi.org/10.1016/j.cancergencyto.2010.08.010
  29. Sager R (1989). Tumor suppressor genes: the puzzle and the promise. Science, 246, 1406-12. https://doi.org/10.1126/science.2574499
  30. Santos LE, Guilhen AC, de Andrade RA, et al (2011). The role of TP53 PRO47SER and ARG72PRO single nucleotide polymorphisms in the susceptibility to bladder cancer. Urol Oncol, 29, 291-4. https://doi.org/10.1016/j.urolonc.2009.03.026
  31. Soulitzis N, Sourvinos G, Dokianakis DN, et al (2002). p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett, 179, 175-83. https://doi.org/10.1016/S0304-3835(01)00867-9
  32. Srivastava P, Jaiswal PK, Singh V, et al (2010). Role of p53 gene polymorphism and bladder cancer predisposition in northern India. Cancer Biomark, 8, 21-8.
  33. Toruner GA, Ucar A, Tez M, et al (2001). P53 codon 72 polymorphism in bladder cancer--no evidence of association with increased risk or invasiveness. Urol Res, 29, 393-5. https://doi.org/10.1007/s002400100218
  34. Williams SG, Stein JP (2004). Molecular pathways in bladder cancer. Urol Res, 32, 373-85. https://doi.org/10.1007/s00240-003-0345-y
  35. Wu WJ, Kakehi Y, Habuchi T, et al (1995). Allelic frequency of p53 gene codon 72 polymorphism in urologic cancers. Jpn J Cancer Res, 86, 730-6. https://doi.org/10.1111/j.1349-7006.1995.tb02461.x
  36. Xu JW, Li CG, Huang XE, et al (2011). Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases. Asian Pac J Cancer Prev, 12, 985-7.
  37. Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6.
  38. Xu H, el-Gewely MR (2001). P53-responsive genes and the potential for cancer diagnostics and therapeutics development. Biotechnol Annu Rev, 7, 131-64. https://doi.org/10.1016/S1387-2656(01)07035-1
  39. Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of $Endostar^{(R)}$ combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
  40. Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev, 11, 1115-8.
  41. Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinumbased chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev, 12, 2291-4.
  42. Ye Y, Yang H, Grossman HB, et al (2008). Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer, 112, 2467-74. https://doi.org/10.1002/cncr.23472
  43. Yu DS, Huang XE, Zhou JN, et al (2012). A Comparative Study on the Value of Anal Preserving Surgery for Aged People with Low Rectal Carcinoma in Jiangsu, China. Asian Pacific J Cancer Prev, (in press).
  44. Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/ Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.
  45. Zhang LQ, Huang XE, Wang J (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a metaanalysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5.
  46. Zhang R, Chen W, Zhang W, et al (2011). Genetic polymorphisms of p53 codon 72 and bladder cancer susceptibility: a hospitalbased case-control study. Genet Test Mol Biomarkers, 15, 337-41. https://doi.org/10.1089/gtmb.2010.0230
  47. Zhang XZ, Huang XE, Xu YL, et al (2012). A Phase II study on voriconazole in treating Chinese patients with malignant hematological disorder and invasive aspergillosis. Asian Pacific J Cancer Prev, (in press).

Cited by

  1. A Phase II Study on Continuous Infusional Paclitaxel and 5-Fu as First-line Chemotherapy for Patients with Advanced Esophageal Cancer vol.13, pp.11, 2012, https://doi.org/10.7314/APJCP.2012.13.11.5587
  2. Comparative Study on Transcatheter Arterial Chemoembolization, Portal Vein Embolization and High Intensity Focused Ultrasound Sequential Therapy for Patients vol.13, pp.12, 2012, https://doi.org/10.7314/APJCP.2012.13.12.6257
  3. ) Combined with Three-dimensional Conformal External Beam Radiotherapy in Treating Patients with Inoperable Esophageal Cancer vol.13, pp.12, 2012, https://doi.org/10.7314/APJCP.2012.13.12.6523
  4. Impact of Low Versus Conventional Doses of Chemotherapy During Transcatheter Arterial Chemo-embolization on Serum Fibrosis Indicators and Survival of Liver Cancer Patients vol.13, pp.9, 2012, https://doi.org/10.7314/APJCP.2012.13.9.4757
  5. Association Between p53 Arg72Pro Polymorphism and the Risk of Human Papillomavirus-related Head and Neck Squamous Cell Carcinoma: A Meta-analysis vol.14, pp.10, 2013, https://doi.org/10.7314/APJCP.2013.14.10.6127
  6. Role of MYH Polymorphisms in Sporadic Colorectal Cancer in China: A Case-control, Population-based Study vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6403
  7. Colorectal Cancer Screening in High-risk Populations: a Survey of Cognition among Medical Professionals in Jiangsu, China vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6487
  8. Pemetrexed as a Component of First-, Second- and Third-line Chemotherapy in Treating Patients with Metastatic Lung Adenocarcinoma vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6663
  9. Helicobacter pylori Infection and the Risk of Colorectal Adenoma and Adenocarcinoma: an Updated Meta-analysis of Different Testing Methods vol.14, pp.12, 2013, https://doi.org/10.7314/APJCP.2013.14.12.7613
  10. In vitro and in vivo Evaluation of the Antitumor Efficiency of Resveratrol Against Lung Cancer vol.14, pp.3, 2013, https://doi.org/10.7314/APJCP.2013.14.3.1703
  11. Potential Predictors of Sensitivity to Pemetrexed as First-line Chemotherapy for Patients with Advanced Non-Squamous NSCLCs vol.14, pp.3, 2013, https://doi.org/10.7314/APJCP.2013.14.3.2005
  12. (Javanica oil emulsion injection) Combined with Chemotherapy for Patients with Gastric Cancer vol.14, pp.3, 2013, https://doi.org/10.7314/APJCP.2013.14.3.2009
  13. Phase II Study of Pemetrexed as Second or Third Line Combined Chemotherapy in Patients with Colorectal Cancer vol.14, pp.3, 2013, https://doi.org/10.7314/APJCP.2013.14.3.2019
  14. ) and Paclitaxel for Treatment of Patients with Metastatic Gastric Cancer vol.14, pp.4, 2013, https://doi.org/10.7314/APJCP.2013.14.4.2591
  15. Intrapleural or Intraperitoneal Lobaplatin for Treatment of Patients with Malignant Pleural Effusion or Ascites vol.14, pp.4, 2013, https://doi.org/10.7314/APJCP.2013.14.4.2611
  16. Phase II Study on Pemetrexed-based Chemotherapy in Treating Patients with Metastatic Gastric Cancer not Responding to Prior Palliative Chemotherapy vol.14, pp.5, 2013, https://doi.org/10.7314/APJCP.2013.14.5.2703
  17. Phase II Study on Breast Conservative Surgery Plus Chemo- and Radiotherapy in Treating Chinese Patients with Early Staged Breast Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3747
  18. Potential Therapeutic Efficacy of Curcumin in Liver Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3855
  19. Hsa-miR-181a-5p Expression and Effects on Cell Proliferation in Gastric Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3871
  20. Risk Assessment on Anastomotic Leakage after Rectal Cancer Surgery: An Analysis of 753 Patients vol.14, pp.7, 2013, https://doi.org/10.7314/APJCP.2013.14.7.4447
  21. ) Combined with Chemotherapy in Treating Patients with Advanced Lung Adenocarcinoma vol.14, pp.8, 2013, https://doi.org/10.7314/APJCP.2013.14.8.4791
  22. Clinical Study on Mannan Peptide Combined with TP Regimen in Treating Patients with Non-small Cell Lung Cancer vol.14, pp.8, 2013, https://doi.org/10.7314/APJCP.2013.14.8.4801
  23. Acidic Pelvic Drainage as a Predictive Factor For Anastomotic Leakage after Surgery for Patients with Rectal Cancer vol.14, pp.9, 2013, https://doi.org/10.7314/APJCP.2013.14.9.5441
  24. Association between the TP53 codon 72 polymorphism and risk of oral squamous cell carcinoma in Asians: a meta-analysis vol.14, pp.1, 2014, https://doi.org/10.1186/1471-2407-14-469
  25. Helicobacter pylori Infection and a P53 Codon 72 Single Nucleotide Polymorphism: a Reason for an Unexplained Asian Enigma vol.15, pp.21, 2014, https://doi.org/10.7314/APJCP.2014.15.21.9171
  26. p53 Status Correlates with the Risk of Recurrence in Non-Muscle Invasive Bladder Cancers Treated with Bacillus Calmette–Guérin: A Meta-Analysis vol.10, pp.3, 2015, https://doi.org/10.1371/journal.pone.0119476
  27. Prognostic Significance of Nestin Expression in pT1 High-Grade Bladder Urothelial Carcinoma Patients Treated with Intravesical BCG vol.15, pp.24, 2014, https://doi.org/10.7314/APJCP.2014.15.24.10813
  28. P53 Polymorphism at Codon 72 is Associated with Keratocystic Odontogenic Tumors in the Thai Population vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.1997
  29. Identification of High Affinity Non-Peptidic Small Molecule Inhibitors of MDM2-p53 Interactions through Structure-Based Virtual Screening Strategies vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3759
  30. Fuzzy clustering demonstrates that codon 72 SNP rs1042522 of TP53 gene associated with HNSCC but not with prognoses vol.36, pp.12, 2015, https://doi.org/10.1007/s13277-015-3677-7
  31. Association of TP53 gene polymorphisms with susceptibility of bladder cancer in Bangladeshi population vol.36, pp.8, 2015, https://doi.org/10.1007/s13277-015-3324-3
  32. Association between MDM2-SNP309 and p53R72P polymorphisms and the risk of bladder cancer in the Mongolian population vol.7, pp.3, 2017, https://doi.org/10.3892/mco.2017.1317